Clinical Trials Directory

Trials / Conditions / Gaucher Disease, Type 3

Gaucher Disease, Type 3

11 registered clinical trials studyying Gaucher Disease, Type 3 — 3 currently recruiting.

StatusTrialSponsorPhase
TerminatedHigh-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)
NCT07285369
Agyany Pharma LTDN/A
Enrolling By InvitationEffect of Enzyme Replacement Therapy on Cardiac Function in Children With Gaucher Disease Type 3
NCT06627543
Noha Osman—
WithdrawnAn Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Dise
NCT05815004
AVROBIOPhase 2 / Phase 3
RecruitingMAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)
NCT05586243
University of Minnesota—
UnknownPhase 1/2 Study of CAN103 in Subjects With Gaucher Disease
NCT05447494
CANbridge (Suzhou) Bio-pharma Co., Ltd.Phase 1 / Phase 2
RecruitingPEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)
NCT04532047
University of California, San FranciscoPhase 1
CompletedA Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
NCT04002830
Ari ZimranPhase 4
TerminatedStudy of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
NCT03746587
ZevraDenmarkPhase 2
Active Not RecruitingVenglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monother
NCT02843035
Genzyme, a Sanofi CompanyPhase 2
WithdrawnThe Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
NCT02528617
Baylor Research InstitutePhase 4
CompletedEfficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
NCT01685216
ShirePhase 1 / Phase 2